 | Up a level |
2018
Miller, K., Heinrich, D., O'Sullivan, J. M., Carles, J., Wirth, M., Nilsson, S., Huang, L., Kalinovsky, J., Heidenreich, A. and Saad, F. (2018). Radium-223 (Ra-223) therapy after abiraterone (Abi): Analysis of symptomatic skeletal events (SSEs) in an international early access program (iEAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Ann. Oncol., 29. S. 287 - 288. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
2017
Zastrow, S., Saad, F., Heinrich, D., Gillessen, S., OSullivan, J., Carles, J., Miller, K., Huang, L., Van Tol, Seeger M., Nilsson, S. and Heidenreich, A. (2017). Radium-223 (Ra-223) in sequence or in concurrent use with abiraterone acetate (AA) or enzalutamide (E) in metastatic castration resistant prostate cancer (mCRPC) patients treated in an international early access program (iEAP). Oncol. Res. Treat., 40. S. 94 - 95. BASEL: KARGER. ISSN 2296-5262
2014
Krebs, K., Boettinger, N., Huang, L., Chmielewski, M., Uckert, W., Abken, H., Heikenwaelder, M., Knolle, P. and Protzer, U. (2014). T CELLS REDIRECTED BY A CHIMERIC ANTIGEN RECEPTOR RECOGNIZING HBSAG EFFICIENTLY CONTROL HBV IN VIVO IN TRANSGENIC MICE. Cytotherapy, 16 (4). S. S9 - 1. OXFORD: ELSEVIER SCI LTD. ISSN 1477-2566